Table 2 Total cost of IVIg use on indications based on evidence category
Indications | Evidence categorya | N | Mean, Standard deviation/Median, IQR (RM) | 95% Confidence interval for mean (RM) | Total cost (RM) |
|---|---|---|---|---|---|
Severe refractory ITP | Ia | 10 | 8877.40 (SD:3598.37) | 6303.28–11,451.52 | 88,774.00 |
Kawasaki disease | Ia | 8 | 2564.38 (SD: 965.23) | 1757.42–3371.33 | 20,515.00 |
Immune thrombocytopenia or ITP | Ia | 4 | 1492.00 (IQR: 1025.75) | 508.46–2289.04 | 5595.00 |
Chronic inflammatory demyelinating polyneuropathy# | Ia | 1 | – | – | 26,110.00 |
Myasthenia gravis | Ib | 9 | 11,936.00 (IQR: 4849.00) | 6236.65–20,785.13 | 121,598.00 |
Guillain–Barre syndrome | Ib | 6 | 14,733.50 (SD: 6472.38) | 7941.15–21,525.85 | 88,401.00 |
Chronic lymphatic leukemia not responding to conventional therapy* | Ib | 2 | 1305.50 (SD: 263.75) | – | 2611.00 |
Multifocal motor neuropathy# | Ib | 1 | – | – | 73,828.96 |
Toxic epidermal necrolysis | IIa | 2 | 14,547.00 (SD: 4747.51) | – | 29,094.00 |
Neonatal jaundice secondary to isoimmunehaemolytic disease of newborn | III | 9 | 373.00 (SD: 0.00) | 373.00–373.00 | 3357.00 |
Systemic lupus erythematous | III | 9 | 12,536.16 (SD: 7679.47) | 6633.19–18,439.12 | 112,825.40 |
Autoimmune encephalitis* | III | 2 | 11,190.00 (SD: 5275.02) | – | 22,380.00 |
Limbic encephalitis* | III | 2 | 13,987.50 (SD: 1318.75) | – | 27,975.00 |
Neonatal alloimmune thrombocytopenia# | III | 1 | – | – | 746.00 |
Other indications with no established evidenceb | Not established | 12 | 5968.00 (SD:5224.42) | 2648.56–9287.44 | 71,616.00 |
Total | 78 | 695,426.36 |